Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma, Non-Hodgkin 1Gastroesophageal Adenocarcinoma 1Depression 1Carcinoma, Transitional Cell 1Anxiety Disorders 1

Interventions

Cisplatin 104Radiotherapy, Intensity-Modulated 59Gemcitabine 53toripalimab 35Fluorouracil 30Docetaxel 30Capecitabine 28Radiotherapy 23Drug Therapy 20camrelizumab 19nimotuzumab 16nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11spartalizumab 10endostar protein 8Paclitaxel 8Cetuximab 8tislelizumab 7pembrolizumab 7Endostatins 7Bevacizumab 7anlotinib 6Radiation 6Endoscopy 6fludarabine 5S 1 (combination) 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Nasopharyngeal Carcinoma × Single Person × Clear all
NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

The University of Hong Kong

Phase 2 Not yet recruiting
53 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡